logo Hematology/Oncology Research Studies: Open for Enrollment Date: 07/19/19


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex

NCT#/Phase: NCT03213665
Phase 2
IRB#: 2017-095c
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of tazemetostat in children with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS tumors) harboring specified activating genetic alterations in EZH2 or members of the SWI/SNF complex. The study aims to determine the objective response rate of EPZ-6438 (tazemetostat), a selective small molecule inhibitor of the histone methyltransferase EZH2.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621C.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Christine Ho (510-428-3885 x 2609)
Diane Olzewski (510-428-3885 x 3246)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03213665#

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000